)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SyntheticMR
SyntheticMR (SYNT) investor relations material
SyntheticMR Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary25 Aug, 2026
Executive summary
Net sales for Q2 2026 increased by 13% year-over-year to 14.0 MSEK, with strong growth in cNeuro and APAC regions.
Operating profit improved to -6.5 MSEK from -8.6 MSEK, and net loss narrowed to -6.1 MSEK from -10.4 MSEK year-over-year.
Cash and cash equivalents rose to 28.3 MSEK at quarter-end, up from 19.4 MSEK last year.
Regulatory approval for CMRI ARIA was obtained in the UK and Switzerland during the quarter.
Leadership changes in the US organization and recruitment of a global CCO to strengthen sales and marketing.
Financial highlights
Q2 net sales: 13,991 TSEK (up 13% year-over-year); H1 net sales: 27,084 TSEK (up 2%).
Q2 operating profit: -6,457 TSEK (margin -46%); H1 operating profit: -12,726 TSEK (margin -47%).
Q2 net profit: -6,089 TSEK; H1 net profit: -12,275 TSEK.
Cash flow from operating activities in Q2: -2,570 TSEK; H1: -6,202 TSEK.
Shareholders’ equity at period end: 125,707 TSEK; equity/assets ratio: 78.2%.
Outlook and guidance
Focus on achieving profitability through increased sales and disciplined cost control.
Capital from the rights issue is being used to strengthen sales, market presence, and strategic partnerships.
Ongoing FDA review for cMRI ARIA in the US; awaiting further feedback.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SyntheticMR
- Sales fell 8% but losses narrowed; recurring revenue and cash position improved.SYNT
Q1 2026 - Q4 sales up 42% YoY, but full-year loss widened; Combinostics acquisition and new approvals key.SYNTQ4 2025
- Q3 sales fell 7% with a large impairment, but strategic moves set up a Q4 growth rebound.SYNTQ3 2025
- Sales grew 4% in Q2, but losses persisted; new CEO and acquisitions drive future growth.SYNTQ2 2025
- Sales dropped 39% in Q3, but regulatory wins and new hires aim to restore growth.SYNTQ3 2024
- Q2 sales fell sharply on North America weakness, but growth and new launches support future outlook.SYNTQ2 2024
- Sales fell 20% in Q1 2025, but recurring revenue and cash flow showed improvement.SYNTQ1 2025
- Sales fell sharply in 2024, but acquisitions and cost controls set up a 2025 turnaround.SYNTQ4 2024
Next SyntheticMR earnings date
Q3 202625 Nov, 2026
SyntheticMR
Next SyntheticMR earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SyntheticMR's innovative software products for MRI shorten exam times and enable more information to be extracted from the images. These benefits create a better patient experience, reducing the time spent in the noisy, claustrophobic bore of the scanner. The company's customers across the globe are realizing cost savings in both their daily clinical workflow, as well as their yearly budgets. SyntheticMR's products manage a wide variety of exams such as Cardiac MRI, Breast MRI and Body MRI, with applications in Cardiology, Neurosurgery and Oncology.